Protease-activated receptor 2 stabilizes Bcl-xL and regulates EGFR-targeted therapy response in colorectal cancer.

Cancer Letters
Weiwei LiHongying Wang

Abstract

The Bcl-2 homolog Bcl-xL is emerging as a key factor in tumorigenesis due to its prominent pro-survival and cell death-independent functions. However, the regulation of Bcl-xL by microenvironment and its implication in cancer therapy of colorectal carcinoma (CRC) are unclear. Here, we demonstrated that Bcl-xL expression was positively associated with protease-activated receptor 2 (PAR2) in CRC. Activation of PAR2 stabilized Bcl-xL protein in a proteasome-dependent manner, whereas E3 ligase RING finger protein 152 (RNF152) accelerated the ubiquitination and degradation of Bcl-xL. RNF152 silencing by specific siRNAs rescued the expression of Bcl-xL in PAR2-deficient cells. Moreover, RNF152 physically interacted with Bcl-xL, which was disturbed by PAR2 activation. Further studies with serial mutation of Bcl-xL revealed that phosphorylation of Bcl-xL at S145 reduced its binding affinity for RNF152 and stabilized Bcl-xL. Importantly, inhibition of PAR2 signaling by its gene silencing or specific chemical inhibitors increased apoptosis induced by different EGFR-targeted therapies. In patient-derived xenograft model, inhibition of PAR2 increased the response of CRC to different EGFR-targeted therapies. These results indicate that PAR2...Continue Reading

References

Jan 5, 2000·The Journal of Biological Chemistry·S KharbandaD Kufe
Sep 13, 2000·The Journal of Allergy and Clinical Immunology·H VliagoftisR Moqbel
Feb 4, 2005·The New England Journal of Medicine·Jeffrey A Meyerhardt, Robert J Mayer
Jul 11, 2006·Journal of Gastroenterology and Hepatology·Hye Seung HanTae Sook Hwang
Mar 27, 2007·Cell·Kylie D MasonBenjamin T Kile
May 22, 2008·World Journal of Gastroenterology : WJG·You-Li ZhangYu Fan
Jan 5, 2011·Protein & Cell·Songling ZhangJie Tang
Feb 1, 2011·Acta histochemica·Yang Jin-SongDe Wei
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Sep 9, 2011·Gut·Natalie SteckDirk Haller
Jan 4, 2012·Nature Reviews. Drug Discovery·Rithwik RamachandranMorley D Hollenberg
Oct 29, 2013·Cell Death and Differentiation·N VolkmannD Hanein
May 9, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ryutaro KajiharaSeiji Inui
Oct 22, 2014·The Journal of Biological Chemistry·Vadim IablokovWallace K MacNaughton
May 8, 2015·Nature Protocols·Lawrence A KelleyMichael J E Sternberg
Aug 19, 2016·Cell Death & Disease·Anna-Lena ScherrBruno Christian Koehler
Dec 7, 2016·Nature Reviews. Clinical Oncology·Cornelis J A PuntLouis Vermeulen
Feb 24, 2018·Biochemical Society Transactions·Ana Serrano-Puebla, Patricia Boya
Dec 12, 2018·Cancer Cell·Delphine MerinoAndreas Strasser
Jan 4, 2019·Nature Cell Biology·Rosalie E Lawrence, Roberto Zoncu
Feb 13, 2019·Inflammatory Bowel Diseases·Weiwei LiHongying Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

© 2021 Meta ULC. All rights reserved